Pacira Pharmaceuticals, Inc. 4
4 · Pacira Pharmaceuticals, Inc. · Filed Jun 14, 2013
Insider Transaction Report
Form 4
Pratt John
General Manager, San Diego
Transactions
- Exercise/Conversion
Common Stock
2013-06-13$10.81/sh+18,232$197,088→ 18,232 total - Exercise/Conversion
Common Stock
2013-06-12$10.81/sh+925$9,999→ 925 total - Sale
Common Stock
2013-06-13$30.00/sh−18,232$546,960→ 0 total - Sale
Common Stock
2013-06-13$30.00/sh−1,875$56,250→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2013-06-12−925→ 130,732 totalExercise: $10.81Exp: 2022-06-04→ Common Stock (925 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2013-06-13−18,232→ 112,500 totalExercise: $10.81Exp: 2022-06-04→ Common Stock (18,232 underlying) - Sale
Common Stock
2013-06-12$30.00/sh−925$27,750→ 0 total - Exercise/Conversion
Common Stock
2013-06-13$8.73/sh+1,875$16,369→ 1,875 total - Exercise/Conversion
Employee Stock Option (right to buy)
2013-06-13−1,875→ 18,750 totalExercise: $8.73Exp: 2022-01-02→ Common Stock (1,875 underlying)
Footnotes (2)
- [F1]The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vests and becomes exercisable as to the remaining shares in successive equal monthly installments for the subsequent 36 months.
- [F2]The option vested and became exercisable as to 25% of the option shares on January 3, 2013 and vests and becomes exercisable as to the remaining shares in successive equal monthly installments at the end of each month over the subsequent 36 months.